Type2 Diabetes Clinical Trial
Official title:
The Attenuating Effect of Soluble Fiber Consumption on Postprandial Glycemia in Humans
Verified date | April 2022 |
Source | Purdue University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of the current study is to investigate whether consumption of soluble fibers (isomaltodextrin [IMD], partially digestible maltodextrin) and RS4 starch will lower postprandial glycemia as well as postprandial insulin in human subjects with relatively high fasting blood glucose, when consumed with a specific amount of digestible carbohydrate (rice porridge). The primary outcome of the study is the effect of fibers on postprandial blood glucose, whereas the secondary outcome will be its effect on postprandial blood insulin.
Status | Completed |
Enrollment | 24 |
Est. completion date | March 9, 2022 |
Est. primary completion date | March 9, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 22 Years to 60 Years |
Eligibility | Inclusion Criteria: - Body mass index (18.5 kg/m² = BMI = 29.9 kg/m²) - No history of abnormal glucose metabolism - No ongoing use of drugs affecting blood glucose levels - Fasting blood glucose between 90-110 mg/dL - Low dietary fiber intake (less than 15 g per day) Exclusion Criteria: - Diabetic individuals - Individuals with history of gastrointestinal disease - Pregnant or nursing women |
Country | Name | City | State |
---|---|---|---|
United States | Purdue University | West Lafayette | Indiana |
Lead Sponsor | Collaborator |
---|---|
Purdue University | Grain processing corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postprandial glycemic response | Blood glucose will be measured, (AUC) | Acute study: [3 hours of measurement after consumption of test food] | |
Primary | Postprandial glycemic response | Blood glucose will be measured, (C max) | Acute study: [3 hours of measurement after consumption of test food] | |
Primary | Postprandial glycemic response | Blood glucose will be measured, (t max) | Acute study: [3 hours of measurement after consumption of test food] | |
Secondary | Postprandial insulin response | Blood insulin will be measured, (AUC) | Acute study: [3 hours of measurement after consumption of test food] | |
Secondary | Postprandial insulin response | Blood insulin will be measured, (C max) | Acute study: [3 hours of measurement after consumption of test food] | |
Secondary | Postprandial insulin response | Blood insulin will be measured, (t max) | Acute study: [3 hours of measurement after consumption of test food] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03239366 -
A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
|
Phase 2 | |
Completed |
NCT04597229 -
Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
|
N/A | |
Completed |
NCT03623139 -
Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT04599920 -
Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)
|
N/A | |
Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
Completed |
NCT04382521 -
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
|
N/A | |
Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
Recruiting |
NCT03458715 -
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Completed |
NCT02974504 -
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
|
Phase 4 | |
Completed |
NCT05053828 -
Type 2 Diabetes With Antiplatelet Drugs
|
||
Not yet recruiting |
NCT03659383 -
The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine
|
Phase 4 | |
Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
Completed |
NCT03979768 -
Risk Assessment of Type 2 Diabetes in Pharmacies
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Active, not recruiting |
NCT04994288 -
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients
|
Phase 2/Phase 3 | |
Completed |
NCT03290768 -
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
|
N/A | |
Enrolling by invitation |
NCT04088851 -
"The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"
|
N/A | |
Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|